Pathologic assessment of vasculopathies in pulmonary hypertension
Giuseppe G. Pietra, MD*,*,
Frederique Capron, MD ,
Susan Stewart, MD ,
Ornella Leone, MD ,
Marc Humbert, MD¶,
Ivan M. Robbins, MD,
Lynne M. Reid, MD|| and
R. M. Tuder, MD**
* Department of Pathology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
Service d'Anatomie Pathologique 1, Hôpital de la Pitié, 83, bd de l'Hôpital 75651 Paris Cedex, 13, France
Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
Department of Pathology, Azienda Ospedaliera S. Orsola-Malpighi of Bologna, Bologna, Italy
¶ Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Assistance Publique, Hôpitaux de Paris, Université Paris-Sud, Clamart, France
Vanderbilt University Medical Center, Adult Pulmonary Hypertension Center, Vanderbilt University, Nashville, Tennessee, USA
|| Department of Pathology, Harvard Medical School, Boston, MassachusettsBaltimore, Maryland, USA
** Division of Cardiopulmonary Pathology, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
Manuscript received November 26, 2003;
accepted February 3, 2004.
*
Reprint requests and correspondence: Dr. Giuseppe G. Pietra, Via San Giorgio 23, CH 6976 Castagnola, Switzerland.
gkpietra{at}freesurf.ch
 |
Abstract
|
|---|
Pulmonary arterial hypertension (PAH) includes various forms of pulmonary hypertension of different etiology but similar clinical presentation and functional derangement. Histopathological vascular changes in all forms of PAH are qualitatively similar but with quantitative differences in the distribution and prevalence of pathological changes in various portions of the pulmonary vascular bed. The documentation of these topographic variations in the response of the pulmonary vasculature to injury may be important to understand the pathogenesis of the various subsets of PAH. To standardize the precise histopathological documentation of the pulmonary vasculopathy in PAH we propose a histopathological classification that includes both the predominant segment of the pulmonary vasculature affected and the possible coexistence of pathological changes in other vascular segments.
|
Abbreviations and Acronyms
| | BMPR2 | = Bone morphometric protein receptor-2 | | HIV | = human immunodeficiency virus | | PAH | = pulmonary arterial hypertension | | PCH | = pulmonary capillary hemangiomatosis | | PM | = pulmonary microvasculopathy | | POV | = pulmonary occlusive venopathy | | PPH | = primary pulmonary hypertension | | PVOD | = pulmonary veno-occlusive disease |
|
The term pulmonary arterial hypertension (PAH) includes a variety of pulmonary hypertensive diseases with different etiologies but similar clinical presentation and, in many cases, similar response to medical treatment (1). Initially, PAH comprised primary pulmonary hypertension (PPH) and pulmonary hypertension related to left-to-right shunts, collagen-vascular diseases, portal hypertension, human immunodeficiency virus (HIV) infection, ingestion of drugs or dietary products, and persistent fetal circulation (1). At the recent Third World Symposium on Pulmonary Artery Hypertension, pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) have been incorporated into PAH because of the high incidence of arteriopathy in these conditions (2,3), the similarity of risk factors with PAH (HIV, drug ingestion), the familial occurrence (4,5), and the recently discovered mutation of bone morphometric protein receptor-2 (BMPR2) in a case of PVOD (6). It has been hypothesized that PAH, PVOD, and PCH may represent part of the spectrum of the same disease, or differing reactions to similar insults.
The Evian classification (1) is based on etiology, clinical presentation, and functional data, and it assumes that all subsets of PAH have a similar spectrum of pathological lesions. This may not always be the case because morphometric studies have shown differences in the distribution and prevalence of arterial changes among PAH of different etiology (7,8). Also, in certain cases of PAH venous changes coexist with arterial lesions; that is, the pulmonary veins and venules can show intimal and adventitial thickening and even arterialization (9–12). In the proximity of organized pulmonary infarcts, veno-occlusive changes can also be present, possibly due to scarring or other disruptions of vascular relationships.
Thus, documentation of the extent of different types of vascular changes among the various subsets of PAH is essential in understanding how various segments of the pulmonary vascular tree react to injury. To standardize pathological reporting and provide clinicians with a precise description of the nature and extent of vascular lesions present in a single case, we have adopted a descriptive histopathologic system of classification (Table 1) in which both the predominant changes and the coexisting pathologic changes are recorded.
|
Handling of lung tissue
|
|---|
Fixation of the lung samples in a state of distension avoids crenation of elastic laminae of muscular pulmonary arteries that may induce a state of spurious medial hypertrophy. Adequate sampling of the lungs (at least five blocks from each lobe) is essential. The histological examination should indicate whether adequate samples of blood vessels are present, the nature and number of diseased blood vessels, the presence, location, and nature of inflammatory cells, as well as any evidence of associated pathology in the airways or lung parenchyma. In addition to hematoxylin-eosin (HE), special histological stains (Movat, Masson, Verhoeff-van Gieson, Perls' iron) are essential to assess vascular pathology. Also useful are immunohistochemical markers for smooth muscle and endothelium (Factor VIII, CD31, CD 34).
|
Pulmonary arteriopathy
|
|---|
All forms of pulmonary hypertension have some common pathologic features regardless of their etiology, that is, medial hypertrophy of muscular and elastic arteries, dilation and intimal atheromas of elastic pulmonary arteries and right ventricular hypertrophy. These forms of pulmonary vascular remodeling have limited diagnostic value because they are present in all forms of severity of pulmonary hypertension. Also, pulmonary artery medial and intimal thickening can occur as an isolated nonspecific finding in localized areas of the lung or secondary to airway or interstitial diseases and tumors, with no direct relationship to the presence or not of pulmonary hypertension.
In addition to the aforementioned pathologic changes common to all forms of pulmonary hypertension, PAH is characterized by constrictive and complex arterial lesions involving to varying degrees the pre- and intra-acinar pulmonary arteries (3,12). The main histopathological features of this pulmonary arteriopathy are illustrated in Figure 1 and are briefly defined below.
View larger version (120K):
[in this window]
[in a new window]
|
Figure 1 Main histopathological features of pulmonary arteriopathy (see text for details). (All histological sections were stained with Verhoeff-van Gieson unless specified.) Medial hypertrophy: (A) preacinar pulmonary artery, x80; (B) intra-acinar artery, x600. Concentric laminar intimal thickening: (C) intra-acinar artery, x500; (D) pre-acinar artery. The vessel was decorated with anti-smooth muscle actin antibodies (SMA), revealing the intimal thickening (white arrow) to be composed of SMA-positive cells, x150. Eccentric (E) x100 and concentric nonlaminar (F) x100 intimal thickening of pre-acinar arteries. Plexiform lesions: (G) intra-acinar artery decorated with SMA showing SMA-negative endothelial cells (arrow) surrounded by a rim of SMA-positive cells (rusty color), x380; (H) pre-acinar artery adjacent to a plexiform lesion (arrow) and dilation lesions (shown by asterisk) x60. (I) Dilation lesions (arrows), x40; (J) colander-like lesion, HE x400; (K) lymphomonocytic arteritis, HE, x300.
|
|
Constrictive lesions.
These lesions include medial hypertrophy, and intimal and adventitial thickening. These changes are believed to result from an imbalance between proliferation and apoptosis of the various cell types forming the vascular walls. Because they are diffuse lesions, they may be hemodynamically important if vasorelaxant properties are lost (i.e., prostacyclin or nitric oxide) or there is excessive production of vasoconstrictors (i.e., endothelin). Medial hypertrophy is an increase in the cross-sectional area of the media of pre- and intra-acinar pulmonary arteries (Figs. 1A and 1B). It is due to both hypertrophy and hyperplasia of smooth muscle fibers and to an increase in connective tissue matrix and elastic fibers in the media of muscular arteries and extension of smooth muscle into nonmuscularized intra-acinar arteries. Medial hypertrophy entails both numerical and phenotypical changes of muscle fibers. Atrophy of the media occurs in arteries with marked intimal thickening and in developing dilation lesions.
Intimal thickening can be of three types: concentric laminar, eccentric, or concentric nonlaminar (Figs. 1C to 1F). Concentric laminar intimal thickening can be to varying degrees either cellular or fibrous (Figs. 1C and 1D). Both ultrastructurally and immunohistochemically, the intimal cells show features of fibroblasts, myofibroblasts, and smooth muscle cells (Fig. 1D). However, these morphologic features do not allow conclusions on their derivation because recent experimental work has shown the potential of endothelial cells and fibroblasts to acquire smooth muscle phenotype (13). Concentric laminar intimal thickening is a characteristic feature of the so-called pulmonary plexogenic arteriopathy and/or of scleroderma arteriopathy. Eccentric and concentric nonlaminar intimal thickenings are predominantly composed of fibroblasts and connective tissue matrix (Figs. 1E and 1F). The notion that these changes are diagnostic of thromboembolic arteriopathy needs revision because intimal thickening may result from localized proliferation of intimal fibroblasts caused by growth factors released by hemodynamic stresses.
Adventitial thickening is difficult to evaluate because of its ill-defined boundaries in conventional histological sections. In most cases of PAH, the adventitia appears uninvolved, but it is expanded in pulmonary hypertension owing to persistent fetal circulation of the newborn.
|
Complex lesions
|
|---|
Plexiform lesions, dilation lesions, and arteritis are classified as complex lesions. They are focal changes important as markers of either the severity or rapid progression of pulmonary hypertension. It has also been suggested that endothelial proliferation in plexiform lesions of PPH may be a marker of a fundamental cellular abnormality, possibly of neoplastic nature (14,15).
The plexiform lesion is a focal proliferation of endothelial channels lined by myofibroblasts, smooth muscle cells, and connective tissue matrix. The lesion is located within pre- and intra-acinar pulmonary arteries and is associated with expansion and partial destruction of the arterial wall with extension of the plexiform lesion into the perivascular connective tissue (Figs. 1G and 1H). Within the plexiform lesion, fibrin thrombi and platelets are frequently present. The plexiform lesion is often located at an arterial branching point, or at the origin of a supernumerary artery, distally to marked obliterative intimal thickening of the parent artery. The frequency of the plexiform lesion in PAH remains undetermined and probably varies to a great extent. Based on studies with limited sampling, it is estimated that the plexiform lesion involves from 20% to 60% of the pulmonary arteries. It is extremely rare in PAH related to connective tissue diseases and it does not occur in PAH of persistent fetal circulation.
The localization of plexiform lesions along the arterial tree also varies; that is, in congenital left-to-right shunts they tend to occur in arteries 100 to 200 µm in external diameter, whereas in PPH they tend to occur in arteries <100 µm (3,12). Plexiform lesions may be difficult to distinguish from the colander-like lesion of recanalized thromboemboli (Fig. 1J). They are no longer considered pathognomonic for PPH as they have been found in PAH associated with other diseases and even in chronic thromboembolic pulmonary hypertension (16). Endothelial cells within plexiform lesions express vascular endothelium growth factor (VEGF) and its receptors (17), and the lesions are believed to result from disordered angiogenesis attributable to autonomous monoclonal endothelial proliferation in the case of PPH (14,15). Recently, the association of the vasculotropic human herpesvirus-8 with plexiform lesions of PPH has been demonstrated (18).
The dilation lesion is a thin-walled vein-like vessel (Figs. 1H and 1I) usually located distally to a plexiform lesion. This lesion may be the source of pulmonary hemorrhages and subsequent organization and fibrosis.
Arteritis is rarely primary in PAH; most often it is associated with other complex lesions. The arterial wall may be necrotic with fibrinoid insudation and/or be infiltrated with chronic and acute inflammatory cells (Fig. 1K).
In our histopathological classification, the terms "pulmonary occlusive venopathy" (POV) and "pulmonary microvasculopathy" (PM) replace the old terms of PVOD and PCH, respectively (Table 1).
Pulmonary occlusive venopathy (POV) (formerly PVOD) accounts for a relatively small proportion of cases of pulmonary hypertension. The diagnosis of POV and PM (described below) in vivo is difficult and is not considered in most patients until signs of marked pulmonary hypertension have developed. Although, by high resolution computed tomography, patchy centrilobular ground-glass opacities, thickened septal lines, pleural effusion, and mediastinal adenopathy are characteristic for POV and PM (19), the cornerstone of the diagnosis of POV/PM is histopathology. The main pathology of POV consists of extensive and diffuse occlusion of pulmonary venules and veins of various sizes (2,5). The occluding fibrous tissue may be loose and edematous with variable cellularity, or dense, sclerotic, and acellular (Fig. 2A). The intimal thickening of POV involves venules and small veins and rarely extends to the larger veins. The luminal occlusion can be either solid or eccentric with multiple lumina (Fig. 2B), suggestive of recanalization of occlusive thrombi. The media of the venules and veins may become thickened with an increase in elastic fibers and smooth muscle (i.e., so-called arterialization). All these morphological features are helpful in distinguishing POV from chronic venous hypertension.
View larger version (175K):
[in this window]
[in a new window]
|
Figure 2 Pulmonary occlusive venopathy. (A) Septal veins with nearly occluded lumens by fibrous intimal thickening (asterisk), marked lymphatic dilation (arrow), and congested alveolar capillaries. Verhoeff-van Gieson staining, x50. (B) Obstructive fibrous intimal thickening and recanalization channels in a septal vein, x200. Pulmonary microvasculopathy. (C) Focal thickening of alveolar septa by proliferated capillaries, HE,x20. (D) Nodular capillary proliferation, hemosiderin-laden alveolar macrophages and type II pneumocytes (arrows), HE, x300.
|
|
A nonspecific but useful histological feature is the presence of calcium-encrusting elastic fibers in the walls of veins or adjacent alveoli. This feature, when present, renders the veins easily identifiable and is therefore a pertinent histological finding when the diagnosis of PVOD (or, indeed, pulmonary hypertension) has not been raised by the referring clinician. Another feature that is useful in distinguishing between POV and chronic passive venous hypertension is the foreign body giant-cell response to the calcium-encrusted elastic fibers. This feature is also helpful when POV is being considered as a supplementary diagnosis to another pulmonary pathology (i.e., interstitial lung disease or emphysema), a circumstance not uncommon in lung explant pathology.
In POV, large amounts of hemosiderin are found both within the cytoplasm of alveolar macrophages and type II pneumocytes as well as deposits in the interstitium. The presence of fresh blood and/or hemosiderin may be so prominent that idiopathic hemosiderosis or healed Wegener's granulomatosis or other vasculitis is suggested. Hemosiderosis can be quite striking, and quantification of occult alveolar hemorrhage in bronchoalveolar lavage (BAL) (19,20) has been successfully used to confirm the clinical diagnosis of POV/PM because BAL hemorrhage is not a usual feature of the other forms of PAH. The capillary vessels are engorged and prominent; they may become so tortuous as to resemble pulmonary capillary hemangiomatosis (21,22). The capillaries are generally easily identifiable within the alveolar septa and do not line both sides of the alveolar walls as seen in PM (PCH).
Pulmonary arteries and arterioles can show remodeling in approximately 50% of POV cases with moderate to severe medial hypertrophy and arterialization. Plexiform lesions and fibrinoid arteritis are not described in POV (2). The pulmonary interstitium shows edema particularly located in the lobular septa, which may progress to interstitial fibrosis. This can be sufficiently extensive to raise the possibility of interstitial lung disease such as usual interstitial pneumonitis. Inflammatory lung disease is further mimicked by the marked lymphocytic interstitial infiltrate that is seen in some cases of POV. Lymphatics within the lung and pleura are dilated in POV (Fig. 2A).
Pulmonary microvasculopathy (formerly PCH) is another rare condition characterized by localized capillary proliferation within the lung in which capillaries invade pulmonary interstitium, vessels, and, less commonly, airways (23). The distribution of PM in the lungs is usually panlobar and patchy, resembling an interstitial process at low magnification and mimicking pulmonary congestion (24). However, closer inspection shows diffuse proliferation of microvessels containing large numbers of erythrocytes (Figs. 2C and 2D). These microvessels can form glomeroloid tufts or nodules that may project into the lumen of veins and lymphatics and within air spaces. A distinguishing feature, which is best appreciated on reticulin staining, is the presence of microvessels on both sides of the alveolar walls. Havlik et al. (25) require the microvessels to form at least two cell layers within the proliferating lesion for diagnosis. The endothelial cells of the abnormal capillaries are cytologically bland with elongated oval nuclei, diffuse chromatin, and indistinct cytoplasm. Mitoses are not frequently seen despite the apparent proliferative nature of the condition. The abnormal proliferating capillaries extend into bronchovascular bundles; they infiltrate the walls of arterioles, arteries, venules, and veins, invading muscular walls and occluding the lumens. Also, microvascular proliferation has been seen in perineural and intraneural positions, in the pleura, and in lymph nodes. Venous occlusion by proliferating capillaries and related intimal fibrosis is distinct from the nonangiogenic occlusion of veins in POV.
In the areas of capillary proliferation, a striking feature is pulmonary hemosiderosis represented by both fresh hemorrhage and abundant hemosiderin-laden macrophages and type II pneumocytes (Fig. 2D). However, cases without striking hemosiderosis are observed. The infiltrating capillaries can mimic plexiform lesions, but neither these nor dilation lesions have been described in PM. Similar to POV, the pulmonary arteries in PM show marked muscular hypertrophy and intimal thickening, but, unlike POV, lesions resembling thrombosis are not a feature.
The pathogenesis of PM (PCH) is controversial. Some investigators consider PM to be neoplastic (26), and it is interesting that some patients with PM have responded to treatment with interferon- , which presumably acts by depressing endothelial proliferation (27,28). Conversely, PM may be due to unknown angiogenic stimuli, and the infiltrative aspect of the disease may merely be related to the extension of vascular lesions within a preexisting vascular distribution.
The PCH/PM-like lesions, as described by Havlik et al. (25), are not associated with clinical pulmonary hypertension and do not generally show invasion of small vessels with occlusion. Pulmonary microvasculopathy and PCH/PM-like lesions must be carefully distinguished from severe pulmonary congestion and atelectasis (29).
Previously PM was described as a possible hypertensive vasculopathy, such lesions had been described as prominent, hyperplastic capillaries with pseudoangiomatous features. Increasing familiarity with the entity of PM has drawn attention to overlaps and similarities between this and POV, particularly in relation to the parenchymal changes of hemosiderosis, fibrosis, lymphatic dilation and edema, and the similar arterial modifications of intimal fibrosis and medial hypertrophy. The distinction between the two entities is clear in those cases where the venous obliteration in PM is due to proliferating capillaries and in POV due to intimal fibrosis with or without recanalization.
Some cases are, however, less clear-cut, and the issue is further confounded by the description of PCH/PM-like lesions that can occur in several clinicopathological settings and that have even been described at autopsy in the absence of evidence of pulmonary hypertension. Clearly, use of the term "PCH/PM-like lesions" must be strict and contextual if confusion is to be avoided. This is an area where there is a likely future role for molecular pathology in distinguishing dilation and tortuosity of existing capillaries from capillary angiogenesis and in elucidating the relationship to vascular remodeling and growth factors. It is important to note that similar microvasculopathy is usual in severe mitral valve disease, and interpretation of venous and capillary congestion with or without proliferation should be made in the knowledge of any valvular disease.
As with many pathological conditions that are poorly understood, it is tempting to consider lesions as part of a continual spectrum, and this view has been justified in relation to POV, POV with PM-like lesions, and true PM, according to whether the venous or capillary lesions are believed to predominate. This can be a hazardous approach if the nature of the sample is not specified. It is likely that explant or autopsy examination of an entire lung will produce a different emphasis on a putative spectrum than will analysis of biopsy material. One point that is abundantly clear, however, is the critical importance of recognizing both POV and PM as rare causes of unexplained pulmonary hypertension because the treatment with vasoactive agents is contraindicated and may even be life-threatening (30,31). Presently, the final distinction between POV and PM requires tissue diagnosis, which is not always feasible. Both the role and the need for lung biopsy in the diagnosis and management of pulmonary hypertension are still under debate.
Pulmonary occlusive venopathy and PM are rather uncommon (fewer than 200 cases have been reported in the published data) but increasingly recognized causes of pulmonary hypertension. They could represent part of the spectrum of vasculopathies of PPH, but they are distinct from the precapillary causes of PAH. The hypertensive angiopathies with exclusive involvement of the precapillary bed share similar morphological lesions of intimal fibrosis, medial hypertrophy, and plexiform lesions, and they generally have a favorable response to drugs such as epoprostenol. Patients with POV and PM may respond to vasodilators with life-threatening edema, and it is therefore of great clinical importance that they be distinguished from precapillary PAH (30,31). It is well recognized that POV in some cases shows extensive abnormality of the pulmonary arterial vascular bed with apparently equal involvement of the venous and arterial components of the circulation. For this situation, the term "pulmonary vascular occlusive disease" has been adopted, but in the current state of pathogenetic knowledge it may itself be confusing (32).
In relation to the second issue, the term pulmonary vascular occlusive disease (or vaso-occlusive) generally denotes extensive involvement of large and small pulmonary arteries by narrowing or occlusion of the same type of intimal fibrosis as seen in the pulmonary veins, indicating that the tendency to thrombosis was not limited to the veins but also affected the arteries. The availability of explant or autopsy tissue may define the main focus of the vascular pathology on either the venous or arterial aspects of the pulmonary circulation (as compared to biopsy material), but there is no doubt that, even with whole lungs to examine, some cases are difficult to classify. Significant advances in the genetics and pathogenesis of pulmonary hypertension may help to resolve these issues.
Additionally, it is now well described that abnormalities in bone morphometric protein receptor-2 (BMPR2) signaling plays a significant role in the majority of familial and in some sporadic cases of pulmonary hypertension. It is therefore fascinating to note a case (6) of POV (PVOD) apparently caused by an inherited mutation in BMPR2. There was no histopathological assessment of the proband mother's pulmonary hypertension, but features characteristic of POV were found in the proband herself (6) upon review of the open-lung biopsy. Interestingly, the patient improved clinically with epoprostenol and has remained stable for many years, which is quite uncommon in POV. It is likely that the systematic and uniform description of the nature and extent of widespread arterial lesions in PVO/PM and the coexistence of venous lesions in PAH, as recommended in the new pathological classification, together with studies of BMPR2, BMPR1a, TIE-2, and angiopoietin expression in the various forms of pulmonary vasculopathy, will provide information about the position of predominantly arterial, venous, capillary, or mixed forms on a clinical and histological spectrum (33). These exciting developments will surely enable a better informed analysis of the links between POV and PCH/PM with precapillary pulmonary hypertension. This may also allow further refinement of PCH-like lesions in these settings and also in chronic pulmonary venous hypertension. Similar studies may shed light on capillary angiogenesis versus congestion and dilation. Primary pulmonary hypertension appears now to be an angioproliferative disease, and PCH/PM may represent uncontrolled angiogenesis, either de novo or arising from a reactive/hyperplastic process.
|
References
|
|---|
1. Rich SE. Primary pulmonary hypertension: executive summary from the World Symposium—primary pulmonary hypertension. http://www.who.int/ncd/cvd/pph.html. 1998.
2. Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Path Anat and Histol. 1974;364:69–79
3. Pietra GG. The pathology of primary pulmonary hypertension. Rubin LJ, Rich S. Primary Pulmonary Hypertension: Lung biology in health and disease. vol 99. New York, NY: Marcel Dekker; 1997. p. 19–61
4. Langleben D, Henegan JM, Batten AP, et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med. 1988;109:106–109
5. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2000;162:1964–1973
6. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in BMPR2. Am J Respir Crit Care Med. 2003;167:889–894
7. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1577–1586
8. Jamison BM, Michel RP. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol. 1995;26:987–993
9. Chazova I, Loyd JE, Zhdanov VS, et al. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol. 1995;146:389–397
10. Leone O, Campidelli C, Manes A, et al. Arterial and venous changes in pulmonary arterial hypertension and veno-occlusive disease. 3rd World Symposium on Pulmonary Arterial Hypertension (abstr). Venice, 2003.
11. Dorfmüller P, Humbert M, Sanchez O, et al. Significant occlusive lesions of pulmonary veins are common in patients with pulmonary hypertension associated to connective tissue diseases. 3rd World Symposium on Pulmonary Arterial Hypertension (abstr). Venice, 2003.
12. Wagenvoort CA, Wagenvoort N. Pathology of pulmonary hypertension. New York, NY: John Wiley; 1977.
13. Fri MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002;90:1189–1196
14. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927–934
15. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 2001;88:e2–e11
16. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–692
17. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999;155:411–419
18. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003;349:1113–1122
19. Rabiller A, Humbert M, Sitbon O, et al. Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: Occult alveolar hemorrhage is a common feature of pulmonary veno-occlusive disease. (abstr)Am J Respir Crit Care Med. 2003;167:A276
20. Capron F. Lavage broncho-alvéolaire et hémorragie alvéolaire. Ann Pathol. 2002;222:782–788
21. Daroca PJ, Mansfield RE, Ichinose H. Pulmonary veno-occlusive disease: report of a case with pseudoangiomatous features. Am J Surg Pathol 1977;1:349–55.
22. Schraufnagel DE, Sekosan M, McGee T, Thakkar MB. Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. Eur Respir J. 1996;9:346–350
23. Wagenvoort CA, Beetsra A, Spijker J. Capillary haemangiomatosis of the lungs. Histopathology. 1978;2:401–406
24. Erbersdobler A, Niendorf A. Multifocal distribution of pulmonary capillary haemangiomatosis. Histopathology. 2002;40:88–91
25. Havlik DM, Massie LW, Williams WL, Crooks LA. Pulmonary capillary hemangiomatosis-like foci. An autopsy study of 8 cases. Am Clin Pathol. 2000;113:655–662
26. Tron V, Magee F, Wright JL, Colby T, Churg A. Pulmonary capillary hemangiomatosis. Hum Pathol. 1986;93:657–659
27. Almagro P, Julia J, Sanjaume M, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: Report of 2 new cases and review of 35 cases from the literature. Medicine. 2002;81:417–424
28. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon-alpha 2a. N Engl J Med. 1989;320:1197–1200
29. Jing X, Yokoi T, Nakamura Y, et al. Pulmonary capillary hemangiomatosis. A unique feature of congestive vasculopathy associated with hypertrophic cardiomyopathy. Arch Pathol Lab Med. 1998;122:94–96
30. Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicat-ing continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Crit Care Med. 1998;157:1681–1685
31. Resten A, Maitre S, Humbert M, et al. Pulmonary arterial hypertension: Thin-section ct predictors of eposprostenol failure. Radiology. 2002;222:782–788
32. Pä
äkkö P, Sutinen S, Remes M, et al. A case of pulmonary vascular occlusive disease: Comparison of post-mortem radiography and histology. Histopathology. 1985;9:253–262
33. Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003;348:500–509
This article has been cited by other articles:
|
|
|
|
 
D. Gopalan, C. McCann, K. Sheares, and N. Screaton
Imaging in pulmonary hypertension, part 3: small vessel diseases
Postgrad. Med. J.,
January 19, 2012;
(2012)
postgradmedj-2011-130276v.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Ikonomou, A. R. Hemnes, G. Bilousova, R. Hamid, J. E. Loyd, A. K. Hatzopoulos, D. N. Kotton, S. M. Majka, and E. D. Austin
Programmatic change: lung disease research in the era of induced pluripotency
Am J Physiol Lung Cell Mol Physiol,
December 1, 2011;
301(6):
L830 - L835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, L. Bertoletti, X. Jais, P. Dorfmuller, L. Price, B. Girerd, O. Sitbon, M. Humbert, and G. Simonneau
Pulmonary hypertension in orphan lung diseases
,
November 28, 2011;
317 - 331.
[Abstract]
[Fulltext]
[PDF]
|
|
|
|
|
|
|
A. R. Hemnes, M. E. Pugh, A. L. Newman, I. M. Robbins, J. Tolle, E. D. Austin, and J. H. Newman
End Tidal CO2 Tension: Pulmonary Arterial Hypertension vs Pulmonary Venous Hypertension and Response to Treatment
Chest,
November 1, 2011;
140(5):
1267 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. T. Lau, A. Manes, D. S. Celermajer, and N. Galie
Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward
Eur. Heart J.,
October 2, 2011;
32(20):
2489 - 2498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, F. Perros, N. Gambaryan, B. Girerd, P. Dorfmuller, L. C. Price, A. Huertas, H. Hammad, B. Lambrecht, G. Simonneau, et al.
C-Kit-Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
July 1, 2011;
184(1):
116 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-C. Jing, Z.-X. Yu, J.-Y. Shen, B.-X. Wu, K.-F. Xu, X.-Y. Zhu, L. Pan, Z.-L. Zhang, X.-Q. Liu, Y.-S. Zhang, et al.
Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study
Am. J. Respir. Crit. Care Med.,
June 15, 2011;
183(12):
1723 - 1729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Koiwa, I. Tsujino, D. Ikeda, H. Ohira, M. Tanino, and M. Nishimura
An autopsy case of pulmonary veno-occlusive disease refractory to imatinib
Eur. Respir. J.,
April 1, 2011;
37(4):
968 - 970.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Price, D. Montani, C. Tcherakian, P. Dorfmuller, R. Souza, N. Gambaryan, M.-C. Chaumais, D. M. Shao, G. Simonneau, L. S. Howard, et al.
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Eur. Respir. J.,
April 1, 2011;
37(4):
813 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barst, S. I. Ertel, M. Beghetti, and D. D. Ivy
Pulmonary arterial hypertension: a comparison between children and adults
Eur. Respir. J.,
March 1, 2011;
37(3):
665 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Olin, S. Abman, R. Grady, D. Ivy, M. Lovell, D. Partrick, and V. Balasubramaniam
A 7-year-old with pulmonary hypertension.
BMJ Case Reports,
January 1, 2011;
2011:
bcr0220113843 - bcr0220113843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. P. Stanzel, S. Lourenssen, D. G. Nair, and M. G. Blennerhassett
Mitogenic factors promoting intestinal smooth muscle cell proliferation
Am J Physiol Cell Physiol,
October 1, 2010;
299(4):
C805 - C817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Saouti, N. Westerhof, P. E. Postmus, and A. Vonk-Noordegraaf
The arterial load in pulmonary hypertension
Eur. Respir. Rev.,
September 1, 2010;
19(117):
197 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Abe, M. Toba, A. Alzoubi, M. Ito, K. A. Fagan, C. D. Cool, N. F. Voelkel, I. F. McMurtry, and M. Oka
Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
Circulation,
June 29, 2010;
121(25):
2747 - 2754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, X. Jais, L. C. Price, L. Achouh, B. Degano, O. Mercier, S. Mussot, E. Fadel, P. Dartevelle, O. Sitbon, et al.
Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
Eur. Respir. J.,
December 1, 2009;
34(6):
1348 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Stenmark, B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure
Am J Physiol Lung Cell Mol Physiol,
December 1, 2009;
297(6):
L1013 - L1032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chen, A. E. Calvert, H. Cui, and L. D. Nelin
Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase
Am J Physiol Lung Cell Mol Physiol,
December 1, 2009;
297(6):
L1151 - L1159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zhang, L. Zhou, Q. Li, J. Liu, W. Yao, and H. Wan
Up-Regulation of Two Actin-Associated Proteins Prompts Pulmonary Artery Smooth Muscle Cell Migration under Hypoxia
Am. J. Respir. Cell Mol. Biol.,
October 1, 2009;
41(4):
467 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. BADESCH, M. D. McGOON, R. J. BARST, V. F. TAPSON, L. J. RUBIN, F. M. WIGLEY, K. M. KRAL, I. H. RAPHIOU, and G. D. CRATER
Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
J Rheumatol,
October 1, 2009;
36(10):
2244 - 2249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Overbeek, M. C. Vonk, A. Boonstra, A. E. Voskuyl, A. Vonk-Noordegraaf, E. F. Smit, B. A. C. Dijkmans, P. E. Postmus, W. J. Mooi, Y. Heijdra, et al.
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy
Eur. Respir. J.,
August 1, 2009;
34(2):
371 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Burke, M. G. Frid, C. L. Kunrath, V. Karoor, A. Anwar, B. D. Wagner, D. Strassheim, and K. R. Stenmark
Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment
Am J Physiol Lung Cell Mol Physiol,
August 1, 2009;
297(2):
L238 - L250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Tuder, S. H. Abman, T. Braun, F. Capron, T. Stevens, P. A. Thistlethwaite, and S. G. Haworth
Development and Pathology of Pulmonary Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S3 - S9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Harch, H. Whitford, and C. McLean
Failure of Medical Therapy in Pulmonary Arterial Hypertension: Is There an Alternative Diagnosis?
Chest,
June 1, 2009;
135(6):
1462 - 1469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1573 - 1619.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation,
April 28, 2009;
119(16):
2250 - 2294.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beghetti and N. Galie
Eisenmenger Syndrome: A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
March 3, 2009;
53(9):
733 - 740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Steiner, O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman
Interleukin-6 Overexpression Induces Pulmonary Hypertension
Circ. Res.,
January 30, 2009;
104(2):
236 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, L. C. Price, P. Dorfmuller, L. Achouh, X. Jais, A. Yaici, O. Sitbon, D. Musset, G. Simonneau, and M. Humbert
Pulmonary veno-occlusive disease
Eur. Respir. J.,
January 1, 2009;
33(1):
189 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Elangbam
Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Veterinary Pathology,
January 1, 2009;
46(1):
10 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rich and M. Rabinovitch
Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension
Circulation,
November 18, 2008;
118(21):
2190 - 2199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chaouat, R. Naeije, and E. Weitzenblum
Pulmonary hypertension in COPD
Eur. Respir. J.,
November 1, 2008;
32(5):
1371 - 1385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perros, D. Montani, P. Dorfmuller, I. Durand-Gasselin, C. Tcherakian, J. Le Pavec, M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, et al.
Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
July 1, 2008;
178(1):
81 - 88.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka
Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone
Am J Physiol Lung Cell Mol Physiol,
July 1, 2008;
295(1):
L71 - L78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J.,
June 1, 2008;
31(6):
1357 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Stewart, J. D. Cogan, M. R. Kramer, W. T. Miller Jr, L. E. Christiansen, M. W. Pauciulo, L. M. Messiaen, G. S. Tu, W. H. Thompson, R. E. Pyeritz, et al.
Is Pulmonary Arterial Hypertension in Neurofibromatosis Type 1 Secondary to a Plexogenic Arteriopathy?
Chest,
September 1, 2007;
132(3):
798 - 808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Bauer, T. M. Moore, and I. F. McMurtry
Rodent models of PAH: are we there yet?
Am J Physiol Lung Cell Mol Physiol,
September 1, 2007;
293(3):
L580 - L582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Arciniegas, M. G. Frid, I. S. Douglas, and K. R. Stenmark
Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
July 1, 2007;
293(1):
L1 - L8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zakrzewicz, M. Hecker, L. M. Marsh, G. Kwapiszewska, B. Nejman, L. Long, W. Seeger, R. T. Schermuly, N. W. Morrell, R. E. Morty, et al.
Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension
Circulation,
June 12, 2007;
115(23):
2957 - 2968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S. Eddahibi, M. Mazmanian, E. Fadel, et al.
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension
Eur. Respir. J.,
May 1, 2007;
29(5):
937 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Frazier, T. J. Franks, T.-L. H. Mohammed, I. H. Ozbudak, and J. R. Galvin
From the Archives of the AFIP: Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis
RadioGraphics,
May 1, 2007;
27(3):
867 - 882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. McMurtry, R. Moudgil, K. Hashimoto, S. Bonnet, E. D. Michelakis, and S. L. Archer
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol,
April 1, 2007;
292(4):
L872 - L878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling
Am J Physiol Lung Cell Mol Physiol,
April 1, 2007;
292(4):
L885 - L897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Assaad, S. M. Kawut, S. M. Arcasoy, E. B. Rosenzweig, J. S. Wilt, J. R. Sonett, and A. C. Borczuk
Platelet-Derived Growth Factor Is Increased in Pulmonary Capillary Hemangiomatosis
Chest,
March 1, 2007;
131(3):
850 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Ryu, M. J. Krowka, K. L. Swanson, P. A. Pellikka, and M. D. McGoon
Pulmonary Hypertension in Patients With Interstitial Lung Diseases
Mayo Clin. Proc.,
March 1, 2007;
82(3):
342 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. McCann, C. T. Gan, A. M. Beek, H. W. M. Niessen, A. V. Noordegraaf, and A. C. van Rossum
Extent of MRI Delayed Enhancement of Myocardial Mass Is Related to Right Ventricular Dysfunction in Pulmonary Artery Hypertension
Am. J. Roentgenol.,
February 1, 2007;
188(2):
349 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation,
September 26, 2006;
114(13):
1417 - 1431.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Zuckerbraun, B. Y. Chin, B. Wegiel, T. R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L. E. Otterbein
Carbon monoxide reverses established pulmonary hypertension
J. Exp. Med.,
September 4, 2006;
203(9):
2109 - 2119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini
Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
Chest,
September 1, 2006;
130(3):
841 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Cogan, M. W. Pauciulo, A. P. Batchman, M. A. Prince, I. M. Robbins, L. K. Hedges, K. C. Stanton, L. A. Wheeler, J. A. Phillips III, J. E. Loyd, et al.
High Frequency of BMPR2 Exonic Deletions/Duplications in Familial Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
September 1, 2006;
174(5):
590 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Marecki, C. D. Cool, J. E. Parr, V. E. Beckey, P. A. Luciw, A. F. Tarantal, A. Carville, R. P. Shannon, A. Cota-Gomez, R. M. Tuder, et al.
HIV-1 Nef Is Associated with Complex Pulmonary Vascular Lesions in SHIV-nef-infected Macaques
Am. J. Respir. Crit. Care Med.,
August 15, 2006;
174(4):
437 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Zabka, F. E. Campbell, and D. W. Wilson
Pulmonary Arteriopathy and Idiopathic Pulmonary Arterial Hypertension in Six Dogs
Veterinary Pathology,
July 1, 2006;
43(4):
510 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert
Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension
Chest,
July 1, 2006;
130(1):
182 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M H Williams, C Das, C E Handler, M R Akram, J Davar, C P Denton, C J Smith, C M Black, and J G Coghlan
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
Heart,
July 1, 2006;
92(7):
926 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rabiller, X. Jais, A. Hamid, A. Resten, F. Parent, R. Haque, F. Capron, O. Sitbon, G. Simonneau, and M. Humbert
Occult alveolar haemorrhage in pulmonary veno-occlusive disease
Eur. Respir. J.,
January 1, 2006;
27(1):
108 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mouthon, L. Guillevin, and M. Humbert
Pulmonary arterial hypertension: an autoimmune disease?
Eur. Respir. J.,
December 1, 2005;
26(6):
986 - 988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zaiman, I. Fijalkowska, P. M. Hassoun, and R. M. Tuder
One Hundred Years of Research in the Pathogenesis of Pulmonary Hypertension
Am. J. Respir. Cell Mol. Biol.,
November 1, 2005;
33(5):
425 - 431.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Rubin and D. B. Badesch
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Ann Intern Med,
August 16, 2005;
143(4):
282 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Richter, M. E. Yeager, A. Zaiman, C. D. Cool, N. F. Voelkel, and R. M. Tuder
Impaired Transforming Growth Factor-{beta} Signaling in Idiopathic Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
December 15, 2004;
170(12):
1340 - 1348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Handling of lung tissue